![Sophia Park](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenienza dei contatti di primo grado di Sophia Park
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Impact Biomedicines, Inc.
![]() Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA.
1
| Subsidiary | Medical Specialties | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Sophia Park tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
MedImmune Ltd.
![]() MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Corporate Officer/Principal | |
AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
ACUTUS MEDICAL, INC. | Medical Specialties | Director/Board Member | |
University of Melbourne
![]() University of Melbourne Other Consumer ServicesConsumer Services The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs. | College/University | Corporate Officer/Principal | |
University of Cambridge | College/University | Doctorate Degree | |
The University of Edinburgh | College/University | Undergraduate Degree | |
MOLECULAR PARTNERS AG | Biotechnology | Director/Board Member | |
Stealthyx Therapeutics Ltd.
![]() Stealthyx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Stealthyx Therapeutics Ltd. operates drug delivery system technology. The company was founded by Yuti Chernajovsky and Eileen Janis Anderson in 2002 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Index Ventures (UK) LLP | Investment Managers | Private Equity Investor | |
Levicept Ltd.
![]() Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Generic | Chairman | |
Morphogen-IX Ltd.
![]() Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Medicxi Ventures (Jersey) Ltd.
![]() Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Investment Managers | Founder | |
Capella Bioscience Ltd.
![]() Capella Bioscience Ltd. Pharmaceuticals: MajorHealth Technology Capella Bioscience Ltd. develops medicines based on monoclonal antibodies to the next generation therapeutic targets in oncology and autoimmune disease. The company was founded by Steve Holmes in 2014 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Inhibitaxin Ltd.
![]() Inhibitaxin Ltd. BiotechnologyHealth Technology Inhibitaxin Ltd. engages in research and development on biotechnology. The company was founded by Simon Lempriere Westbrook and Kevin S. Johnson in 2013 and is headquartered in Kent, the United Kingodm. | Biotechnology | Founder | |
ApcinteX Ltd.
![]() ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
UltraHuman Ltd.
![]() UltraHuman Ltd. Miscellaneous Commercial ServicesCommercial Services UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Rebalance (Cambridge) Ltd.
![]() Rebalance (Cambridge) Ltd. Miscellaneous Commercial ServicesCommercial Services Rebalance (Cambridge) Ltd. provides research and experimental development on biotechnology. The company was founded on December 6, 2016 and is headquartered in Hatfield, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member |
Statistiche
Distribuzione geografica
Regno Unito | 15 |
Stati Uniti | 5 |
Australia | 2 |
Paesi Bassi | 2 |
Svizzera | 2 |
Settori
Health Technology | 13 |
Commercial Services | 5 |
Consumer Services | 4 |
Finance | 3 |
Posizioni
Director/Board Member | 13 |
Corporate Officer/Principal | 3 |
Chairman | 2 |
Founder | 2 |
Private Equity Investor | 2 |
Contatti più connessi
Insiders | |
---|---|
Kevin Johnson | 22 |
- Borsa valori
- Insiders
- Sophia Park
- Connessioni Società